Roka Bioscience (ROKA) Reaches $2.20 Low on Jul, 18; Ensco PLC (ESV) Sentiment Is 1.13

July 18, 2017 - By Adrian Erickson

Ensco plc is an offshore contract drilling company. The company has market cap of $1.61 billion. The Firm provides offshore contract drilling services to the international gas and oil industry. It has a 2.25 P/E ratio. The Company’s divisions include Floaters, Jackups and Other.

The stock of Roka Bioscience Inc (NASDAQ:ROKA) reached all time low today, Jul, 18 and still has $2.02 target or 8.00% below today’s $2.20 share price. This indicates more downside for the $10.99 million company. This technical setup was reported by Barchart.com. If the $2.02 PT is reached, the company will be worth $879,200 less. About 15,332 shares traded. Roka Bioscience Inc (NASDAQ:ROKA) has declined 50.49% since July 18, 2016 and is downtrending. It has underperformed by 67.19% the S&P500.

Analysts await ENSCO PLC (NYSE:ESV) to report earnings on July, 26 after the close. They expect $-0.09 earnings per share, down 117.65% or $0.60 from last year’s $0.51 per share. After $-0.04 actual earnings per share reported by ENSCO PLC for the previous quarter, Wall Street now forecasts 125.00% negative EPS growth.

Ratings analysis reveals 83% of Ensco’s analysts are positive. Out of 6 Wall Street analysts rating Ensco, 5 give it “Buy”, 0 “Sell” rating, while 1 recommend “Hold”. ESV was included in 6 notes of analysts from September 21, 2016. The rating was upgraded by Citigroup on Wednesday, January 11 to “Buy”. The stock of ENSCO PLC (NYSE:ESV) has “Buy” rating given on Monday, January 9 by Bank of America. The firm has “Mkt Perform” rating given on Friday, October 28 by FBR Capital. The rating was upgraded by Goldman Sachs to “Buy” on Wednesday, September 21. The stock of ENSCO PLC (NYSE:ESV) has “Outperform” rating given on Friday, December 2 by Bernstein. The rating was upgraded by Credit Suisse to “Outperform” on Friday, February 3.

About 4.95 million shares traded. ENSCO PLC (ESV) has declined 23.23% since July 18, 2016 and is downtrending. It has underperformed by 39.93% the S&P500.

Key Group Holdings (Cayman) Ltd. holds 4.36% of its portfolio in ENSCO PLC for 4.81 million shares. Oceanic Investment Management Ltd owns 910,320 shares or 3.72% of their US portfolio. Moreover, Messner & Smith Theme Value Investment Management Ltd Ca has 3.69% invested in the company for 232,543 shares. The Jersey-based Contrarius Investment Management Ltd has invested 2.98% in the stock. Cwh Capital Management Inc., a Washington-based fund reported 436,740 shares.

Among 5 analysts covering Roka Bioscience (NASDAQ:ROKA), 2 have Buy rating, 0 Sell and 3 Hold. Therefore 40% are positive. Roka Bioscience has $10 highest and $1 lowest target. $5.75’s average target is 161.36% above currents $2.2 stock price. Roka Bioscience had 9 analyst reports since August 14, 2015 according to SRatingsIntel. As per Monday, March 7, the company rating was downgraded by Leerink Swann. On Friday, August 14 the stock rating was maintained by Leerink Swann with “Outperform”. The company was upgraded on Tuesday, September 8 by Zacks. The stock of Roka Bioscience Inc (NASDAQ:ROKA) earned “Buy” rating by TH Capital on Tuesday, December 13. The firm earned “Buy” rating on Tuesday, December 13 by Roth Capital. The company was downgraded on Tuesday, August 25 by Zacks.

Roka Bioscience, Inc. is a molecular diagnostics company. The company has market cap of $10.99 million. The Firm is focused on the development and commercialization of molecular assay technologies for the detection of foodborne pathogens under the Atlas brand name. It currently has negative earnings. The Firm offers Atlas Detection Assays and Atlas instrument in the North American food safety testing market and has rights to develop and commercialize its molecular testing solutions for a range of other industrial applications.